Genomic data profiled from 207 soft-tissue sarcoma patients revealed that the most common copy number alteration was the amplification of MDM2 that occurred in 56 (27.1%) of the samples [53]; however, when considering just uterine sarcomas, MDM2 was only found to be amplified in 6/108 (5.6%) and when narrowing this down further to specifically uLMS, in only 3/80 (3.8%) [54], suggesting that amplification of MDM2 in uLMS patients is not a common event. Here, MDM2 is linked to soft tissue sarcoma.